Abstract
AbstractIn the early days of peritoneal dialysis (PD) therapy, its limited duration and peritoneal deterioration were argued to be its disadvantages. Biocompatible solutions and hybrid therapy have been used in Japan to overcome these issues, which resulted in a decrease in encapsulating peritoneal sclerosis (EPS) incidence and an extension of PD continuation; these results have been disseminated worldwide. Peritoneal dialysis outcomes and practice patterns study (PDOPPS), a prospective observational study, has begun to confirm the outcomes of PD therapy, and sufficient evidence has been published, which has influenced the preparation of PD guidelines. Current thinking about PD emphasizes the need to maintain quality of life and life goals as care goals for patients and to provide high-quality care. However, we must conduct basic research on the prevention of peritoneal deterioration.
Publisher
Springer Science and Business Media LLC
Subject
Transplantation,Urology,Nephrology
Reference31 articles.
1. Scribner BH, Caner JE, Buri R, Quinton W. The technique of continous hemodialysis. Trans Am Soc Artif Intern Organs. 1960;6:88–103.
2. Popovich RP, Moncrief JW. The determination of a novel portable/wearable equilibrium peritoneal dialysis technique. ASAIO. 1976;5:64.
3. Popovich RP, Moncrief JW, Nolph KD, Ghods AJ, Twardowski ZJ, Pyle WK. Continuous ambulatory peritoneal dialysis. Ann Intern Med. 1978;88:449–56.
4. Shaldon S, Koch KM, Quellhorst E, Lonnemann G, Dinarello CA. CAPD is a second-class treatment. Contrib Nephrol. 1985;44:163–72.
5. Nomoto Y, Kawaguchi Y, Kubo H, Hirano H, Sakai S, Kurokawaet K. Sclerosing encapsulating peritonitis in patients undergoing continuous ambulatory peritoneal dialysis: a report of the Japanese Sclerosing Encapsulating Peritonitis Study Group. Am J Kidney Dis. 1996;28:420–7.